|Articles|April 1, 1995

Oncology NEWS International

Oncology NEWS International Vol 4 No 4
Volume 4
Issue 4

$2 Billion Budget for NCI Proposed

WASHINGTON--President Clinton proposed an FY 1996 budget of $1.994 billion for the National Cancer Institute. This marks an increase of $78 million over FY 1995. The proposed 1996 appropriation for the National Institutes of Health is $11.793 billion, a 4% increase over the current year.

WASHINGTON--President Clinton proposed an FY 1996 budget of $1.994billion for the National Cancer Institute. This marks an increaseof $78 million over FY 1995. The proposed 1996 appropriation forthe National Institutes of Health is $11.793 billion, a 4% increaseover the current year.

Articles in this issue

over 31 years ago

Article

First Results of Avicidin Trials

over 31 years ago

Article

Chemo Patients Often Develop Menstrual Irregularities

over 31 years ago

Article

Growth Factor Receptor Blockade Moving From Laboratory to Clinic

over 31 years ago

Article

Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation

over 31 years ago

Article

Vinorelbine Plus Chemo Promising in Advanced Disease

over 31 years ago

Article

Bone Substudy a Part of Tamoxifen Prevention Trial

over 31 years ago

Article

Ultrasound Breast Screens Useful in Selected Women

over 31 years ago

Article

New Roles Forecast for Endocrine Therapy

over 31 years ago

Article

Antisense Drug Against BCL-2 Effective in Animal Cancer Models

over 31 years ago

Article

Anticancer Drugs From Zeneca in Regulatory Phase of Development

Stay up to date on recent advances in the multidisciplinary approach to cancer.

$2 Billion Budget for NCI Proposed

Articles in this issue

Related Content

BMI, Not Implant Size Mismatch, May Best Predict MSFN Risk

Alcohol-Attributable Cancer Mortality Has Doubled in the US Since 1990

Why Do Upsized Implants Show Lower Mastectomy Skin Flap Necrosis Rates?

How Radiation Oncologists Can Champion World Radiotherapy Awareness Day

How Will Ropeginterferon Alfa’s Approval Impact Essential Thrombocythemia?

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Kansas Society of Clinical Oncology

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Satellite Symposia at the Annual Radiation Oncology Meeting

27th Annual International Lung Cancer Congress®

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Nevada Oncology Society

Louisiana Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Optimizing Multidisciplinary Care in TGCT

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Trending on CancerNetwork

Alcohol-Attributable Cancer Mortality Has Doubled in the US Since 1990

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

Unpacking Iberdomide’s FDA Approval and The Future of CELMoDs

How Will Ropeginterferon Alfa’s Approval Impact Essential Thrombocythemia?

Why Do Upsized Implants Show Lower Mastectomy Skin Flap Necrosis Rates?